| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Cristina Laguna Benetti-Pinto, Andrea Prestes Nácul, Ana Carolina Japur de Sá Rosa-E-Silva, Gustavo Arantes Rosa Maciel, Vania Dos Santos Nunes Nogueira, Paula Condé Lamparelli Elias, Manoel Martins, Leandro Kasuki, Heraldo Mendes Garmes, Andrea Gleze. Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Archives of endocrinology and metabolism. vol 68. 2024-04-05. PMID:38578473. |
dopamine agonists are the first line of treatment for patients with symptomatic hyperprolactinemia due to prolactinomas and in those with idiopathic hyperprolactinemia. |
2024-04-05 |
2024-04-07 |
Not clear |
| Sunita M C De Sousa, Alistair K Jukes, Nicholas G Candy, Ian M Chapman, David J Torpy, Brindha Shivalingam, Peter-John Wormald, Stephen Santoreneo. Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern. Nature reviews. Endocrinology. 2024-03-21. PMID:38509199. |
tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern. |
2024-03-21 |
2024-03-23 |
Not clear |
| Stephan Petersenn, Maria Fleseriu, Shlomo Melme. Reply to 'Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'. Nature reviews. Endocrinology. 2024-03-21. PMID:38509200. |
reply to 'tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'. |
2024-03-21 |
2024-03-23 |
Not clear |
| Lukas Andereggen, Emanuel Chris. Commentary: Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. Frontiers in endocrinology. vol 15. 2024-03-21. PMID:38510701. |
commentary: clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. |
2024-03-21 |
2024-03-23 |
Not clear |
| Oleksandr Voznyak, Iaroslav Zinkevych, Andrii Lytvynenko, Nazarii Hryniv, Roman Ilyuk, Nazarii Kobylia. Prognostic factors for surgical treatment of prolactin-secreting pituitary adenomas. Frontiers in surgery. vol 11. 2024-02-20. PMID:38375408. |
usually, prolactinomas are treated with dopamine agonists (da). |
2024-02-20 |
2024-02-22 |
Not clear |
| E A Giraldi, A Saindane, G Pradilla, V Biousse, A G Ioachimesc. TEMPORAL LOBE HERNIATION AND CHIASMOPATHY DURING DOPAMINE AGONIST THERAPY FOR PROLACTINOMA. Acta endocrinologica (Bucharest, Romania : 2005). vol 19. issue 3. 2024-02-15. PMID:38356985. |
temporal lobe herniation and chiasmopathy during dopamine agonist therapy for prolactinoma. |
2024-02-15 |
2024-02-17 |
Not clear |
| E A Giraldi, A Saindane, G Pradilla, V Biousse, A G Ioachimesc. TEMPORAL LOBE HERNIATION AND CHIASMOPATHY DURING DOPAMINE AGONIST THERAPY FOR PROLACTINOMA. Acta endocrinologica (Bucharest, Romania : 2005). vol 19. issue 3. 2024-02-15. PMID:38356985. |
dopamine agonists (da) are first line treatment for prolactinomas. |
2024-02-15 |
2024-02-17 |
Not clear |
| Jianhua Cheng, Weiyan Xie, Yiyuan Chen, Yingxuan Sun, Lei Gong, Hongyun Wang, Chuzhong Li, Yazhuo Zhan. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. vol 73. 2024-01-26. PMID:38277755. |
the treatment of dopamine agonists (da) resistant prolactinomas remains a formidable challenge, as the mechanism of resistance is still unclear, and there are currently no viable alternative drug therapies available. |
2024-01-26 |
2024-01-29 |
Not clear |
| Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchett. A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas. Global & regional health technology assessment. vol 11. 2024-01-17. PMID:38230389. |
prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (da) therapy like cabergoline. |
2024-01-17 |
2024-01-19 |
Not clear |
| Zhengyuan Chen, Xuefei Shou, Lijin Ji, Haixia Cheng, Ming Shen, Zengyi Ma, Wenqiang He, Zhao Ye, Yichao Zhang, Nidan Qiao, Qilin Zhang, Yongfei Wan. Presurgical Medical Treatment in Prolactinomas: Surgical Implications and Pathological Characteristics from 290 Cases. The Journal of clinical endocrinology and metabolism. 2024-01-02. PMID:38163969. |
to review experience regarding the treatment of prolactinomas by endoscopic endonasal surgery (ees) focusing on the association between presurgical dopamine agonist (da) treatment and perioperative outcomes, surgical morbidities, endocrine outcomes and pathological characteristics. |
2024-01-02 |
2024-01-05 |
Not clear |
| Umar S Durrani, Satvik Vasireddy, Maha Z Arshad, Awais Paracha, Maria A Paracha, Fatima Waheed, Ali Abid, Zohair Siddiqui, Michael Thomur. The Effect of Antipsychotics on Prolactinoma Growth: A Radiological and Serological Analysis. Cureus. vol 15. issue 11. 2023-12-25. PMID:38143631. |
dopamine is also a known negative modulator of the prolactin pathway, which allows for drug agents like dopamine agonists (das) to be incredibly effective in managing tumors that secrete excess prolactin (prolactinomas). |
2023-12-25 |
2023-12-27 |
Not clear |
| Umar S Durrani, Satvik Vasireddy, Maha Z Arshad, Awais Paracha, Maria A Paracha, Fatima Waheed, Ali Abid, Zohair Siddiqui, Michael Thomur. The Effect of Antipsychotics on Prolactinoma Growth: A Radiological and Serological Analysis. Cureus. vol 15. issue 11. 2023-12-25. PMID:38143631. |
the effect of individual antipsychotics on prolactinoma size was difficult to ascertain, as imaging was not obtained (or indicated) after every antipsychotic switch, and many patients were taking dopamine agonists concurrently. |
2023-12-25 |
2023-12-27 |
Not clear |
| Keitaro Shiraishi, Takuya Akai, Takahiro Tomita, Ryuji Hayashi, Takashi Minamisaka, Satoshi Kurod. Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report. Neuropathology : official journal of the Japanese Society of Neuropathology. 2023-12-15. PMID:38099404. |
a dopamine agonist administered for prolactinoma treatment and pituitary stimulation tests are reported as risk factors for pituitary apoplexy. |
2023-12-15 |
2023-12-17 |
Not clear |
| Linjie Wang, Xiaojing Wang, Fengying Gong, Hui Pan, Huijuan Zh. Clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. Frontiers in endocrinology. vol 14. 2023-12-14. PMID:38093965. |
clinical characteristics of male prolactinoma patients mainly presenting with severe obesity and the metabolic response to dopamine agonist therapy. |
2023-12-14 |
2023-12-17 |
Not clear |
| Diana Zúñiga, M A M Stumpf, A L S Monteiro, A Gleze. Correction: Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review. Journal of endocrinological investigation. 2023-12-12. PMID:38079105. |
correction: aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review. |
2023-12-12 |
2023-12-17 |
Not clear |
| Ingrid Marijke Zandbergen, Kristin Michelle Huntoon, Timothy G White, Leontine Erica Henriëtte Bakker, Marco Johanna Theodorus Verstegen, Luma Mudhafar Ghalib, Wouter Ralph van Furth, Iris Catharina Maria Pelsma, Amir R Dehdashti, Nienke Ruurdje Biermasz, Daniel M Prevedell. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series. Archives of medical research. 2023-12-01. PMID:38040527. |
endoscopic transsphenoidal surgery (etss) for prolactinoma is reserved for dopamine agonist (da) resistance, intolerance, or apoplexy. |
2023-12-01 |
2023-12-10 |
Not clear |
| D G Z Guerrero, M A M Stumpf, A L S Monteiro, A Gleze. Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review. Journal of endocrinological investigation. 2023-11-08. PMID:37938428. |
aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review. |
2023-11-08 |
2023-11-20 |
Not clear |
| Mohammad Salem Baba, Bashir Ahmad Laway, Raiz Ahmad Misgar, Arshad Iqbal Wani, Mir Iftikhar Bashir, Imtiyaz Ahmad Bhat, Malik Gawharul Haq, Zafar Amin Sha. Metabolic Abnormalities, Inflammatory Markers and Endothelial Dysfunction in Hyperprolactinemia due to Prolactinoma before and after Normalization of Serum Prolactin: A Prospective Case Control Study. Indian journal of endocrinology and metabolism. vol 27. issue 4. 2023-10-24. PMID:37867992. |
limited work has been done on end in prolactinomas and we, therefore, studied serum markers of inflammation and end in patients with prolactinomas before and after treatment with dopamine agonists. |
2023-10-24 |
2023-11-08 |
Not clear |
| Ernesto Sosa-Eroza, Etual Espinosa-Cárdena. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited. Archives of medical research. 2023-10-08. PMID:37806785. |
long-term discontinuation of dopamine agonist treatment in patients with prolactinomas revisited. |
2023-10-08 |
2023-10-15 |
Not clear |
| Ernesto Sosa-Eroza, Etual Espinosa-Cárdena. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited. Archives of medical research. 2023-10-08. PMID:37806785. |
the most common type of functioning pituitary adenomas is prolactinomas; unlike other types, they are treated medically with dopamine agonists (da). |
2023-10-08 |
2023-10-15 |
Not clear |